Patent Application Covers Glucagon Formulations for Use with Insulin Pumps and Artificial Pancreas
SAN DIEGO, CA, US, January 17, 2019 /EINPresswire.com/ — LATITUDE Pharmaceuticals Inc., a specialized formulation developer for the biotech and pharma industries, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) related to its patent application covering a stabilized soluble glucagon formulation (“Pumpagon”). Thus, a USPTO patent examiner has determined that LATITUDE’s Pumpagon formulation is entitled to a patent under US patent law. Other Pumpagon-related international patent applications are pending.
“We are highly pleased the USPTO has recognized the novelty and industrial utility of our simple and inexpensive approach for keeping glucagon solubilized and stable in an aqueous pumpable solution,” noted Andrew X. Chen, LATITUDE’s President. “Since Pumpagon is more stable than presently marketed glucagon formulations and because it does not contain any new, irritating or unapproved ingredients, our formulation could have a very short development path to become the glucagon formulation of choice for use with the dual hormone insulin/glucagon pumps (artificial pancreas), as well as for mini-dose glucagon administration to treat children with Type 1 diabetes, two emerging diabetes therapies that will be enabled by the multi-day stable Pumpagon.”
LATITUDE’s Pumpagon can be prepared using common approved injectable ingredients or by combining a marketed dextrose solution and a lyophilized glucagon, which are both FDA-approved and have decades of proven clinical safety. Given the extensive familiarity and proven safety of its components, Pumpagon may have immediate utility for a greatly accelerated FDA approval process for use in treating diabetes.
About LATITUDE Pharmaceuticals Inc.
LATITUDE is a developer of innovative drug formulations and drug delivery systems for the biotech and pharmaceutical industries. The company is highly regarded for its intellectual property-generating and innovative approaches to developing pharmaceutical formulations for problematic and/or highly insoluble drug molecules.
For more information, please contact:
Matthew A. Singer, PhD
VP, Head of Business Development
Tel: 858-546-0924, ext. 103
Source: EIN Presswire